printer-friendly version (PDF) - Reflex Sympathetic Dystrophy ...
printer-friendly version (PDF) - Reflex Sympathetic Dystrophy ...
printer-friendly version (PDF) - Reflex Sympathetic Dystrophy ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
EMERGING TREATMENT AND DIAGNOSIS | MANNING<br />
11. Watkins LR, Maier SF. Glia: a novel drug discovery target for clinical pain.<br />
Nat Rev Drug Discov. 2003; 2:973-985.<br />
12. Weihe E, et al. Molecular anatomy of the neuroimmune connection. Int J<br />
Neurosci. 1991; 59:1-23.<br />
13. Maier SF, Watkins LR. Cytokines for psychologists: implications of bidirectional<br />
immune-to-brain communication for understanding behavior,<br />
mood, and cognition. Psychol Rev. 1998; 105:83-107.<br />
14. Meyers C. Mood and cognitive disorders in cancer patients receiving<br />
cytokine therapy. In: Dantzer R1 (Ed). Cytokines, Stress and Depression.<br />
New York: Plenum. 1999, pp 75-82.<br />
15. Balschun D, et al. Interleukin-6: a cytokine to forget. FASEB J. 2004;<br />
18:1788-1790.<br />
16. Ignatowski TA, et al. Brain-derived TNF-alpha mediates neuropathic pain.<br />
Brain Res. 1999; 841:70-77.<br />
17. Ignatowski TA, et al. Neuronal-associated tumor necrosis factor (TNF<br />
alpha): its role in noradrenergic functioning and modification of its<br />
expression following antidepressant drug administration. J Neuroimmunol.<br />
1997; 79:84-90.<br />
18. Huygen, FJ, et al. Mast cells are involved in inflammatory reactions during<br />
complex regional pain syndrome type 1. Immunological Letters.<br />
2004; 91:147-154.<br />
19. Alexander, GM., et al. Changes in cerebrospinal fluid levels of pro-inflammatory<br />
cytokines in CRPS. Pain; 116(3):213-219, 2005.<br />
20. Hashizume H, Rutkowski MD, Weinstein JN, DeLeo JA. Central administration<br />
of methotrexate reduces mechanical allodynia in an animal model<br />
of radiculopathy/sciatica. Pain. 2000b; 87:159-169.<br />
21. Sweitzer SM, DeLeo JA. The active metabolite of leflunomide, an<br />
immunosuppressive agent, reduces mechanical sensitivity in a rat<br />
mononeuropathy model. J Pain. 2002; 3:360-368.<br />
22. Youssef S, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes<br />
a Th2 bias and reverses paralysis in central nervous system autoimmune<br />
disease. Nature. 2002; 420:78-84.<br />
23. Menge T, Hartung HP, Stuve O. Statins-a cure-all for the brain? Nat Rev<br />
Neurosci 2005; 6:325-331.<br />
24. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate<br />
inhibit the induction of nitric oxide synthase and cytokines in rat<br />
primary astrocytes, microglia, and macrophages. J Clin Invest. 1997;<br />
100:2671-2679.<br />
25. Stuve O, Youssef S, Steinman L, Zamvil SS. Statins as potential therapeutic<br />
agents in neuroinflammatory disorders. Curr Opin Neurol. 2003;<br />
16:393-401.<br />
26. Perez J, et al. Dietary fat and protein interact in suppressing neuropathic<br />
pain-related disorders following a partial sciatic ligation injury in rats.<br />
Pain. 2004; 111:297-305.<br />
27. Lehnardt S, et al. Activation of innate immunity in the CNS triggers nedegeneration<br />
through a toll-like receptor 4-dependent pathway. Proc Natl<br />
Acad Sci USA. 2003; 100:8514-8519.<br />
28. Hwang D. Modulation of the expression of cyclo-oxygenase-2 by fatty<br />
acids mediated through toll-like receptor 4-derived signaling pathways.<br />
FASEB J. 2001; 15:2556-2564.<br />
29. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not<br />
unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated<br />
through toll-like receptor 4. J Biol Chem. 2001; 276:16683-16689.<br />
30. Weatherill AR, et al. Saturated and polyunsaturated fatty acids reciprocally<br />
modulate dendritic cell functions mediated through TLR4. J<br />
Immunol. 2005; 174:5390-5397.<br />
31. Tanga FY, Nutile-McMenemy N, DeLeo JA. The CNS role of toll-like receptor<br />
4 in innate neuroimmunity and painful neuropathy. Proc Natl Acad<br />
Sci USA. 2005; 102:5856-5861.<br />
32. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side<br />
effects of glucocorticoids. Pharmacol Ther. 2002; 96:23-43.<br />
33. Karppinen J,et al. Tumor necrosis factor-alpha monoclonal antibody,<br />
infliximab, used to manage severe sciatica. Spine. 2003; 28:750-753.<br />
34. Genevay S, Stingelin S, Gabay C. Efficacy of etanercept in the<br />
treatment of acute, severe sciatica: a pilot study. Ann Rheum<br />
Dis. 2004; 63:1120-1123.<br />
35. Korhonen T, et.al. The treatment of disc herniation-induced sciatica with<br />
infliximab: Results of a randomized, controlled, 3-month follow-up study.<br />
Spine. 2005; 30: 2724-2728.<br />
36. Huygen FJ, et.al. Successful treatment of CRPS-1 with anti-TNF. J Pain<br />
Symptom Manage. 2004; 27:101-103.<br />
37. Hallegua DS, Weisman MH. Potential therapeutic uses of interleukin 1<br />
receptor antagonists in human diseases. Ann Rheum Dis. 2002; 61:960-<br />
967.<br />
38. Corral LG, et al. Differential cytokine modulation and T-cell activation by<br />
two distinct classes of thalidomide analogues that are potent inhibitors<br />
of TNF-alpha. J Immunol. 1999; 163:380-386.<br />
39. Peterson PK, et al. Thalidomide inhibits tumor necrosis factor-alpha production<br />
by lipopolysaccharide- and lipoarabinomannan-stimulated<br />
human microglial cells. J Infect Dis. 1995; 172:1137-1140.<br />
40. Rajikumar, SV, et al. Complete resolution of reflex sympathetic dystrophy<br />
with thalidomide treatment. Archives of Internal Medicine; 20:2502-<br />
2503, 2001.<br />
41. Prager J, et al. Open-label clinical experience of thalidomide in the treatment<br />
of complex regional pain syndrome type I. The Journal of Pain;<br />
4(2):68, 2003.<br />
42. Schwartzman, R, et al. Open-label trial of thalidomide in the treatment of<br />
complex regional pain syndrome type I. The Journal of Pain; 4(2):76,<br />
2003.<br />
43. Bengston K, et al. A phase II study of thalidomide in the treatment of<br />
chronic complex region pain syndrome (CRPS). The Journal of Pain;<br />
4(2):85, 2003.<br />
44. Schwartzman R, et al. A multicenter, open-label, 12-week study with<br />
extension to evaluate the safety and efficacy of lenalidomide (CC-5013)<br />
in the treatment of complex regional pain syndrome type-1. pg 580 in:<br />
Abstracts: 11th World Congress on Pain. IASP Press, Seattle. 2005.<br />
DONALD C. MANNING,<br />
MD, PhD, Executive Director,<br />
Neurosciences Clinical<br />
Research and Development<br />
Celgene Corporation,<br />
Summit, New Jersey<br />
Clinical Associate Professor<br />
of Anesthesiology and Pain<br />
Management, University of<br />
Virginia, Health Sciences<br />
Center, Charlottesville, Virginia<br />
62 | T H E PA I N P R A C T I T I O N E R | S P R I N G 2 0 0 6